The development pipeline of new TB drugs.

<p>OBR: optimized background regimen; EBA: Early Bactericidal Activity study; DS-TB: Drug susceptible tuberculosis; MDR-TB: Multi-drug resistant tuberculosis. Sources: the Stop TB Partnership Working Group on New Drugs, 2015—<a href="http://www.newtbdrugs.org/" target="_blank">www.newtbdrugs.org</a>. Details for projects listed can be found at <a href="http://www.newtbdrugs.org/pipeline.php" target="_blank">http://www.newtbdrugs.org/pipeline.php</a> and ongoing projects without a lead compound series identified can be viewed at <a href="http://www.newtbdrugs.org/pipeline-discovery.php" target="_blank">http://www.newtbdrugs.org/pipeline-discovery.php</a>.</p

The development pipeline of new TB diagnostics.

<p>Sources: WHO Global TB Programme, 2015—<a href="http://www.who.int/tb/publications/global_report/en/" target="_blank">http://www.who.int/tb/publications/global_report/en/</a>; Foundation for Innovative New Diagnostics (FIND)— <a href="http://www.finddiagnostics.org/resource-centre/presentations/find_symposium_capetown_2015/index.html" target="_blank">http://www.finddiagnostics.org/resource-centre/presentations/find_symposium_capetown_2015/index.html</a>. Disclaimer: The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization or are preferred over others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.</p